GB201513740D0 - Muscarinic agonist - Google Patents
Muscarinic agonistInfo
- Publication number
- GB201513740D0 GB201513740D0 GBGB1513740.9A GB201513740A GB201513740D0 GB 201513740 D0 GB201513740 D0 GB 201513740D0 GB 201513740 A GB201513740 A GB 201513740A GB 201513740 D0 GB201513740 D0 GB 201513740D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- muscarinic agonist
- muscarinic
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000472 muscarinic agonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1513740.9A GB201513740D0 (en) | 2015-08-03 | 2015-08-03 | Muscarinic agonist |
| PCT/GB2016/052384 WO2017021728A1 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| CA2994143A CA2994143C (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| JP2018504993A JP6847093B2 (ja) | 2015-08-03 | 2016-08-03 | ムスカリン様アゴニスト |
| EP16750221.0A EP3331528B1 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| AU2016302047A AU2016302047B2 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| US15/749,743 US10548884B2 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| ES16750221T ES2894855T3 (es) | 2015-08-03 | 2016-08-03 | Agonistas muscarínicos |
| DK16750221.0T DK3331528T3 (da) | 2015-08-03 | 2016-08-03 | Muskarinagonister |
| CN201680045225.6A CN107949384B (zh) | 2015-08-03 | 2016-08-03 | 毒蕈碱激动剂 |
| HK18109573.6A HK1250139B (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| US16/728,762 US11324738B2 (en) | 2015-08-03 | 2019-12-27 | Muscarinic agonists |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1513740.9A GB201513740D0 (en) | 2015-08-03 | 2015-08-03 | Muscarinic agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201513740D0 true GB201513740D0 (en) | 2015-09-16 |
Family
ID=54063147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1513740.9A Ceased GB201513740D0 (en) | 2015-08-03 | 2015-08-03 | Muscarinic agonist |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10548884B2 (OSRAM) |
| EP (1) | EP3331528B1 (OSRAM) |
| JP (1) | JP6847093B2 (OSRAM) |
| CN (1) | CN107949384B (OSRAM) |
| AU (1) | AU2016302047B2 (OSRAM) |
| CA (1) | CA2994143C (OSRAM) |
| DK (1) | DK3331528T3 (OSRAM) |
| ES (1) | ES2894855T3 (OSRAM) |
| GB (1) | GB201513740D0 (OSRAM) |
| WO (1) | WO2017021728A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2619829T3 (es) | 2011-11-18 | 2017-06-27 | Heptares Therapeutics Limited | Agonistas del receptor muscarínico M1 |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US10329289B2 (en) | 2015-12-23 | 2019-06-25 | Merck Sharp & Dohme Corp. | 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2019183636A1 (en) * | 2018-03-23 | 2019-09-26 | Pfizer Inc. | Piperazine azaspiro derivaves |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| BR112022005420A2 (pt) * | 2019-09-25 | 2022-06-21 | Oncoarendi Therapeutics Sa | Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina |
| CR20220153A (es) * | 2019-10-09 | 2022-05-03 | Novartis Ag | Derivados de 2–azaespiro [3.4] octano como agonistas de m4 |
| UY38906A (es) * | 2019-10-09 | 2021-05-31 | Novartis Ag | Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos |
| ES2983860T3 (es) | 2019-12-06 | 2024-10-25 | Neurocrine Biosciences Inc | Antagonistas del receptor muscarínico 4 y métodos de uso |
| JP7707176B2 (ja) * | 2020-02-05 | 2025-07-14 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | ムスカリン性受容体４アンタゴニストおよび使用方法 |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| WO2025030095A1 (en) * | 2023-08-03 | 2025-02-06 | Neurocrine Biosciences, Inc. | Methods of synthesis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2642649A1 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| WO2007100664A2 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| JP2012506883A (ja) | 2008-10-29 | 2012-03-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換されたスピロアミン |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| ES2619829T3 (es) * | 2011-11-18 | 2017-06-27 | Heptares Therapeutics Limited | Agonistas del receptor muscarínico M1 |
| EP2897948B1 (en) * | 2012-09-18 | 2016-08-31 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
| JP6478923B2 (ja) * | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート |
| EP4413985A3 (en) * | 2014-02-06 | 2024-10-23 | Nxera Pharma UK Limited | Pharmaceutical compounds |
| GB201504675D0 (en) * | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
-
2015
- 2015-08-03 GB GBGB1513740.9A patent/GB201513740D0/en not_active Ceased
-
2016
- 2016-08-03 US US15/749,743 patent/US10548884B2/en active Active
- 2016-08-03 CA CA2994143A patent/CA2994143C/en active Active
- 2016-08-03 DK DK16750221.0T patent/DK3331528T3/da active
- 2016-08-03 ES ES16750221T patent/ES2894855T3/es active Active
- 2016-08-03 WO PCT/GB2016/052384 patent/WO2017021728A1/en not_active Ceased
- 2016-08-03 CN CN201680045225.6A patent/CN107949384B/zh active Active
- 2016-08-03 JP JP2018504993A patent/JP6847093B2/ja active Active
- 2016-08-03 EP EP16750221.0A patent/EP3331528B1/en active Active
- 2016-08-03 AU AU2016302047A patent/AU2016302047B2/en active Active
-
2019
- 2019-12-27 US US16/728,762 patent/US11324738B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2994143A1 (en) | 2017-02-09 |
| US11324738B2 (en) | 2022-05-10 |
| HK1250139A1 (en) | 2018-11-30 |
| EP3331528B1 (en) | 2021-09-29 |
| JP2018522034A (ja) | 2018-08-09 |
| AU2016302047A8 (en) | 2018-03-08 |
| ES2894855T3 (es) | 2022-02-16 |
| CN107949384A (zh) | 2018-04-20 |
| WO2017021728A9 (en) | 2017-04-27 |
| DK3331528T3 (da) | 2021-10-25 |
| JP6847093B2 (ja) | 2021-03-24 |
| EP3331528A1 (en) | 2018-06-13 |
| AU2016302047A1 (en) | 2018-02-15 |
| WO2017021728A1 (en) | 2017-02-09 |
| US20200129496A1 (en) | 2020-04-30 |
| CA2994143C (en) | 2023-09-26 |
| CN107949384B (zh) | 2025-02-28 |
| US20180228791A1 (en) | 2018-08-16 |
| AU2016302047B2 (en) | 2020-09-10 |
| US10548884B2 (en) | 2020-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201800715B (en) | Muscarinic agonists | |
| GB201513740D0 (en) | Muscarinic agonist | |
| GB201501297D0 (en) | Device | |
| GB201513743D0 (en) | Muscarinic agonists | |
| SG11201607458QA (en) | Muscarinic receptor agonists | |
| GB2537033B (en) | Device | |
| PL3328248T3 (pl) | Ulepszone przesuwne pionowo urządzenie do zawieszania ubrań | |
| SG11201708455YA (en) | Shutoff-opening device | |
| GB201521136D0 (en) | Device | |
| GB201515777D0 (en) | Device | |
| TWI562713B (en) | Elcetronic device | |
| HUE056371T2 (hu) | Átömlesztõ eszköz | |
| EP3265466A4 (en) | Peripheral-anticholinergic muscarinic agonist combination | |
| GB201519583D0 (en) | Device | |
| ZA201704941B (en) | Pondage device | |
| PL3350533T3 (pl) | Urządzenie tłumiące odrzut | |
| GB201610183D0 (en) | Structure | |
| PT3391016T (pt) | Amostrador | |
| IL237991A0 (en) | Player | |
| ZA201807587B (en) | Polytunnel structure | |
| GB201610190D0 (en) | Structure | |
| PT3075370T (pt) | Dispositivo de automassagem | |
| GB201520882D0 (en) | Device | |
| GB201520322D0 (en) | Device | |
| GB201513473D0 (en) | Device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |